pennsy DEPARTMENT	/lvania OF HUMAN SERVICES	MEDICAL ASSISTANCE BULLETIN				
ISSUE DATE	EFFECTIVE DATE	NUMBER				
January 26, 2021	December 1, 2020	01-20-62, 08-20-65, 09-20-60, 24-20-54, 31-20-62, 33-20-57				
SUBJECT SARS-CoV-2	2 Vaccine Updates	BY Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs				

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <u>https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx</u>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers about updates related to billing and payment for the administration of the novel coronavirus (SARS-CoV-2) vaccines, effective December 1, 2020.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospital clinics, independent medical surgical clinics, and licensed pharmacies enrolled in the MA Program who administer immunizations to MA beneficiaries in the Fee-for-Service delivery system (FFS) or through the MA managed care organizations (MCOs) in Physical Health HealthChoices and Community HealthChoices. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate MCO with any billing questions.

BACKGROUND/DISCUSSION:

On November 10, 2020, the Centers for Medicare & Medicaid (CMS) established new Current Procedure Terminology (CPT) codes for the administration of the SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. These codes are both distinct to each SARS-CoV-2 vaccine and the specific dose in the required schedule. This level of

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx. specificity offers the ability to track each vaccine dose, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

On December 1, 2020, the Department added these CPT codes to the MA Program Fee Schedule for providers to use when billing the MA Program for the administration of the SARS-CoV-2 vaccines manufactured by Pfizer, Inc. and Moderna, Inc. These codes are to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

On December 24, 2020, the Department issued MAB 01-20-59, "Addition to the Medical Assistance Program Fee Schedule for Administration of SARS-CoV-2 Vaccines," to inform providers about the addition of these codes. The MAB advised providers that the administration fee was \$10.00.

On December 30, 2020, the Department issued MAB 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists," announcing that the MA Program will pay pharmacies for the administration of the SARS-CoV-2 Vaccine in accordance with a licensed pharmacist's authority to administer vaccines.

After discussion with medical providers and other stakeholders, the Department made the decision to increase the MA Program fee schedule rate to that of Medicare for the administration of the SARS-CoV-2 vaccines.

Additionally, on December 17, 2020, CMS established new CPT codes for the administration of the vaccine manufactured by AstraZeneca. In response, the Department will add these codes to the MA Program Fee Schedule, effective February 1, 2021, and available upon the approval of the Emergency Use Authorization by the U.S. Food and Drug Administration. These codes are to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

MA providers in both the FFS and managed care delivery systems are to bill for the administration of the SARS-CoV-2 vaccines to MA beneficiaries using the CPT codes below.

Vaccine Manufacturer	<u>Code</u>	Code Description
Pfizer, Inc.	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
Flizer, inc.	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose

Moderna,	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
Inc.	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseases [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
	0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose
AstraZeneca	0022A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose

Attached is the "Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccine, Effective December 1, 2020". The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure codes for providers submitting MA FFS claims.

The MA Program fee schedule rate increase for the administration of the SARS-CoV-2, vaccine is effective December 1, 2020. The Department will reprocess claims submitted between December 1, 2020 and the issuance of this bulletin. Providers do not need to resubmit the claims.

The MA Program does not make direct payments to licensed pharmacists. Pharmacies may submit an 837 Professional (837P) claim to the MA Program for the administration of the vaccines by a pharmacist using the procedure codes as identified above. The billing and rendering provider for the administration fee claim should be the MA-enrolled pharmacy's National Provider Identifier (NPI). An MA-enrolled prescriber's NPI should be submitted in the referring provider field.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at: <u>https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx</u>.

As a reminder, MA providers may submit a separate NCPDP claim to the Department for the vaccine ingredient cost for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at: <u>https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx</u>.

Providers may not bill the MA Program for a vaccine they receive at no cost, including SARS-CoV-2 vaccines purchased by the federal government.

Additional information and guidance pertaining to the COVID-19 vaccines can be found at the following links:

- American Medical Association <u>https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance</u>.
- Centers for Disease Control and Prevention
 <u>https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html</u>.
- Centers for Medicare & Medicaid Services
 <u>https://www.medicaid.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html</u>.
- PA Department of Health 1-877-PA HEALTH (1-877-724-3258) <u>https://www.health.pa.gov/Pages/default.aspx.</u>

ATTACHMENT:

Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccines, Effective December 1, 2020

			Decemb	er 1, 2020					
			Provider	Place of	Pricing	Informational		Prior Authorization	
Procedure Code	National Code Description	Provider Type	Specialty	Service	Modifier	Modifier	MA Fee	Required	Limits
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (Coronavirus disease [COVID-19])								
	vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage,								
0001A	diluent reconstituted; first dose	01	183	22			\$16.94	No	once per d
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (Coronavirus disease [COVID-19])								
	vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage,								
0001A	diluent reconstituted; first dose	08	082	49			\$16.94	No	once per d
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (Coronavirus disease [COVID-19])								
	vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage,			11, 12, 31,					
0001A	diluent reconstituted; first dose	09	All	32			\$16.94	No	once per d
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (Coronavirus disease [COVID-19])								
	vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage,			11, 31, 32,					
0001A	diluent reconstituted; first dose	24	240, 247	99			\$16.94	No	once per d
	Immunization administration by								
	intramuscular injection of severe acute								
	respiratory syndrome coronavirus 2 (SARS-								
	CoV-2) (Coronavirus disease [COVID-19])								
	vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage,			11, 12, 31,					
0001A	diluent reconstituted; first dose	31	All	32			\$16.94	No	once per d

	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19])							
0001A	vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	33	335	11, 12		\$16.94	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	01	183	22		\$28.39	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	08	082	49		\$28.39	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	09	All	11, 12, 31, 32		\$28.39	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	24	240, 247	11, 31, 32, 99		\$28.39	No	once per day

		1		1	1	1	1	1
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	31	All	11, 12, 31, 32		\$28.39	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, processitive free 20 mgg (0 2ml decage							
0002A	preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	33	335	11, 12		\$28.39	No	once per day
0002A	Immunization administration by		333	11, 12		Ş20.39	NO	once per day
	intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage;							
0011A	first dose	01	183	22		\$16.94	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	08	082	49		\$16.94	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage;			11, 12, 31,				
0011A	first dose	09	All	32		 \$16.94	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage;			11, 31, 32,				
0011A	first dose	24	240, 247	99		\$16.94	No	once per day

r								
	Immunization administration by							
	intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,							
	preservative free, 100 mcg/0.5mL dosage;			11, 12, 31,				
0011A	first dose	31	All	32		\$16.94	No	once per day
	Immunization administration by							
	intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,							
	preservative free, 100 mcg/0.5mL dosage;							
0011A	first dose	33	335	11, 12		\$16.94	No	once per day
	Immunization administration by			,				. ,
	intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,							
	preservative free, 100 mcg/0.5mL dosage;							
0012A	second dose	01	183	22		\$28.39	No	once per day
	Immunization administration by	01	100			<i></i>		
	intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,							
	preservative free, 100 mcg/0.5mL dosage;							
0012A	second dose	08	082	49		\$28.39	No	once per day
0012/1	Immunization administration by	00	002	15		Ş20.55	110	ence per ady
	intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,							
	preservative free, 100 mcg/0.5mL dosage;			11, 12, 31,				
00124	second dose	00	A.II	32		ć20.20	Ne	onco nor dav
0012A	Immunization administration by	09	All	52		\$28.39	No	once per day
	intramuscular injection of severe acute							
	2							
	respiratory syndrome coronavirus 2 (SARS-							
	CoV-2) (Coronavirus disease [COVID-19])							
	vaccine, mRNA-LNP, spike protein,			11 21 22				
00101	preservative free, 100 mcg/0.5mL dosage;	2.5	240.017	11, 31, 32,		400 00	N :	
0012A	second dose	24	240, 247	99		\$28.39	No	once per day

Immunization administration by Intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CV-2) (Coronavirus disease (CVDI-59) vaccine, MRNA-LNP. Spile protein, escend doze second doze second doze munication administration by Intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CV-2) (Coronavirus disease (CVDI-59) vaccine, MRNA-LNP. Spile protein, espiratory syndrome coronavirus 2 (SARS- CV-2) (Coronavirus disease (CVDI-59) vaccine, MRNA-LNP. Spile protein, espiratory syndrome coronavirus 2 (SARS- CV-2) (Coronavirus disease (CVDI-59) vaccine, MRNA-LNP. Spile protein, espiratory syndrome coronavirus 2 (SARS- CV-2) (Coronavirus disease (CVDI-59) vaccine, MRNA-LNP. Spile protein, chimpanze adenovirus Oxford 1 (Ch4OADI) vector, perservative free, SA1DIO viral 0021A* particles/OSmit dosege; Trist dose 0012 munication administration by Intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CV-2) (coronavirus 2 (SARS- CV-2) (coronavirus disease (CVDI-59) vaccine, DNA, Spile protein, chimpanze adenovirus Oxford 1 (Ch4OADI) vector, perservative free, SA1DIO viral particles/OSmit dosege; Trist dose 0021A* particles/OSmit dosege; Trist dose 0021A* particles/OSmi					1	1			
respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease (COMD-91)) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0 5mL dosage; 31 All 32 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease (COMD-91)) vaccine, mRNA-LNP, spike protein, preservative free, 500 mcg/0 5mL dosage; 33 335 11, 12 Minutization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease (COMD-91)) vaccine, mRNA-LNP, spike protein, preservative free, 500 mcg/0 5mL dosage; 33 335 11, 12 Minutization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease (COMD-91)) vaccine, DNA, spike protein, chimpanzee adenovirus Ddord 1 (ChAdOXI) vector, preservative free, SADD Vial oo21A* Minutizion administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease) (COMD-91) vaccine, DNA, spike protein, chimpanzee adenovirus Ddord 1 (ChAdOXI) vector, preservative free, SADD Vial oo21A* Minutizion administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease) (COMD-91) vaccine, DNA, spike protein, chimpanzee adenovirus Ddord 1 (ChAdOXI) vector, preservative free, SADD Vial output disease (COV-91) vaccine, DNA, spike protein, chimpanzee adenovirus dosage) (SIM dosage) Minutizion administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease) (COV-91) vaccine, DNA, spike protein, chimpanzee adenovirus dosage) (SIM dosage) Minutizion administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SABS- GOV-2) (coronavirus disease) (COV-91) vaccine, DNA, spike protein, chimpanzee adenovirus dosage) (COV-91) vaccine, DNA, spike protein, chimpanzee adenovirus dosage) (COV-91) vacci									
CoV-2) (coronavirus disease (COVD-19)) All 32 S28.39 No once per day 0012A second dose 31 All 32 S28.39 No once per day 0012A intranuscular injection of severa scute respiratory synchrome coronavirus (SdARS- CoV-2) (coronavirus disease (COVD-19)) No once per day vaccine, mRAL-NP, spike protein, preservative free, 100 mcg/0.5mL dosage: 33 335 11, 12 S28.39 No once per day 0012A second dose 33 335 11, 12 S28.39 No once per day vacine, mRAL-NP, spike protein, preservative free, 100 mcg/0.5mL dosage: 33 335 11, 12 S28.39 No once per day 0012A second dose 33 335 11, 12 S28.39 No once per day 0012A second dose 33 335 11, 12 S28.39 No once per day 0021A* admovinus dissase (COV-19) second dose 11, 12 S28.39 No once per day 0021A* admovinus dissase (COV-19) second dose 01 183 22 S16.94 No <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
vaccine, mRNA-LNP, splke protein, preservative free, 100 mcg/0.5mL dosage; second dose3.1All3.2528.39Noonce per day0012AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, splke protein, preservative free, 100 mcg/0.5mL dosage; second dose3.33.3511, 12528.39Noonce per day0012Asecond dose3.33.3511, 12528.39Noonce per day0012Aintramuscular injection of severe acute respiratory syndrome coronavirus 3 (SARS- CoV-2) (coronavirus 3 (SARS- COV-2)									
o012Apreservative free, 100 mcg/0.5mL dosage; second dose31All32528.39Noonce per dayimmunization administration by intramuscular injection of severe acute respiratory syndrome corranvirus (2588- CoV-2) (coronavirus disease) (COVID-19)) vaccine, mRNA-LNP, Spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- CoV-2) (coronavirus disease) (COVID-19)) vaccine, mRNA-LNP, Spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- CoV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- CoV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19)) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corranvirus 2(5885- COV-2) (coronavirus disease) (COVID-19) vaccine, DNA, spike protein, Almanzee a denovirus Over acute respiratory syndrome corra									
0012Asecond dose31All32528.39Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (COROnavirus disease (COVID-19)) vaccine, mNA-LNP, spile protein, preservative free, 5x010 viral3333511, 12528.39Noonce per day0012Asecond dose3333511, 12528.39Noonce per day0012Asecond dose0118322516.94Noonce per day0021A*particle/0.5mL dosage, first dose0118322516.94Noonce per day0021A*particle/0.5mL dosage, first dose0808249516.94Noonce per day0021A*particle/0.5mL dosage, first dose0808249516.94Noonce per day0021A*particle/0.5mL dosage, first dose0808249516.94Noonce per day0021A*particle/0.5mL dosage, first dose0808249									
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (Coronavirus disease (COVID-19)) vaccine, mRN-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; 33 335 11, 12 528.39 No once per day 0012A second dose 33 335 11, 12 0012A second dose 33 335 11, 12 immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral ouzacine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, 08 062 49 \$16.34 No once per day									
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mt dosage; 3333511, 12\$28.39Noonce per day0012Aimmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOAI) vector, preservative free, \$X0100 viral particles/0.5mt dosage; first dose0118322\$16.94Noonce per day0021A*immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOAI) vector, preservative free, \$X0100 viral particles/0.5mt dosage; first dose0118322\$16.94Noonce per day0021A*immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOAI) vector, preservative free, \$X0100 viral particles/0.5mt dosage; first dose0808249\$16.94Noonce per day0021A*immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOAI) vector, respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee <td>0012A</td> <td></td> <td>31</td> <td>All</td> <td>32</td> <td></td> <td>\$28.39</td> <td>No</td> <td>once per day</td>	0012A		31	All	32		\$28.39	No	once per day
respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose 33 335 11, 12 528.39 No once per day intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4OX1) vector, preservative free, 5x101 viral 0021A* particles/0.5mL dosage; first dose 01 183 22 516.94 No once per day intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)] vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4OX1) vector, preservative free, 5x101 viral 0021A particles/0.5mL dosage; first dose 01 183 22 516.94 No once per day intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)] vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4OX1) vector, preservative free, 5x101 viral 0021A particles/0.5mL dosage; first dose 082 49 516.94 No once per day									
C0-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 5001 order 0.5mL dosage; second dose3333511, 12528.39Noonce per day0012AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SRRS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Cord 1 (ChAdOX1) vector, preservative free, 5x010 viral intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Cord 1 (ChAdOX1) vector, preservative free, 5x010 viral particles/0.5mL dosage; first dose0118322S16.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Cord 1 (ChAdOX1) vector, preservative free, 5x1010 viral perservative free, 5x1010 viral per									
vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose3333511, 12\$28.39Noonce per day0012AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral 0021A*11, 12\$16.94Noonce per day0012AImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0118322\$16.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Dxford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A*Immunization administration by 									
0012Apreservative free, 100 mcg/0.5mL dosage; second dose3333511, 12\$28.39Noonce per dayImmunization administration by intramuscular injection of sever acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus DXford 1 (ChAdOX1) vector, preservative free, 5x1010 viral intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus DXford 1 (ChAdOX1) vector, preservative free, 5x1010 viral intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus DXford 1 (ChAdOX1) vector, preservative free, 5x1010 viral D021A *00118322\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus DXford 1 (ChAdOX1) vector, preservative free, 5x1010 viral preservative free, 5x1010 vir									
0012Asecond dose3333511, 12528.39Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0118322516.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0118322516.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus 2 (SARS- COV-2) (
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19)) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral No once per day 0021A * particles/0.5mL dosage; first dose 01 183 22 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 01 183 22 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 01 183 22 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day 0021A * particles/0.5mL dosage; first dose 08 082 49 \$16.94 No <td< td=""><td></td><td>preservative free, 100 mcg/0.5mL dosage;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>		preservative free, 100 mcg/0.5mL dosage;							
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SAR5- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral18322\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SAR5- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral00118322\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SAR5- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A *Immunization administration by 	0012A	second dose	33	335	11, 12		\$28.39	No	once per day
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral18322\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral0118322\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease (COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease (COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (Ch4dOx1) vector,0808249\$16.94Noonce per day									
respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral D021A * particles/0.5mL dosage; first dose 01 183 22 516.94 No once per day intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral 0021A * particles/0.5mL dosage; first dose 08 082 49 516.94 No once per day intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose 08 082 49 516.94 No once per day		,							
CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first doseO118322S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral0808249S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus 3 disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0 Xiford 1 (chAdOX1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus 2 (SARS- COV-2) (coronavirus 3 disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0 Xiford 1 (chAdOX1) vector,Immunization administration by intramuscular in		-							
vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viralImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first doseImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first doseOBOB249Immunization spike spike spike spike spike spikeNoonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first doseOBOB249Spike spike spike spike spike0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee a denovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrom									
adenovirus Oxford 1 (ChAdOX1) vector, preservative free, Sx1010 viral particles/0.5mL dosage; first dose0118322S16.94Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, Sx1010 viral particles/0.5mL dosage; first dose0808249S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, Sx1010 viral particles/0.5mL dosage; first dose0808249S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector,0808249S16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector,AllImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector,Immunization administration by intramusc									
preservative free, 5x1010 viral particles/0.5mL dosage; first dose0118322S16.94Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector,Rand PARRand <b< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></b<>									
0021A*particles/0.5mL dosage; first dose0118322\$16.94Noonce per dayImmunization administration by intranuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249\$16.94Noonce per day0021A*Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector,0808249\$16.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0Xford 1 (ChAdOX1) vector,Immunization administration administration									
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day 0021A * Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, 08 082 49 \$16.94 No once per day		•							
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose080824949516.94Noonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus 0xford 1 (ChAdOX1) vector,Allow and an	0021A *	particles/0.5mL dosage; first dose	01	183	22		\$16.94	No	once per day
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOX1) vector,		Immunization administration by							
respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,									
CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first doseO8O8249SinceSinceNoonce per day0021A *Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe, by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe, by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute intramuscular injection									
vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose 08 082 49 \$16.94 No once per day Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,									
adenovirus Oxford 1 (ChAdOX1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose080824911 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
preservative free, 5x1010 viral particles/0.5mL dosage; first dose0808249100\$16.94Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,Immunization administration by intramuscular injection of severe acute intramuscular injection of severe acute intramuscular injection of severe acute 									
0021A *particles/0.5mL dosage; first dose0808249\$16.94Noonce per dayImmunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,080824910\$16.94Noonce per day									
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,	00214 *		09	092	40		¢16.04	No	once per dav
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,	UUZIA '	particles/0.5me uosage, mst uose	00	082	49		Ş10.94	UVI	once per udy
intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,		Immunization administration by							
respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,									
CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,									
vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,									
adenovirus Oxford 1 (ChAdOx1) vector,		, (, , , , , , , , , , , , , , , , , ,							
preservative free, 5x1010 viral 11, 12, 31,					11, 12, 31,				
0021A * particles/0.5mL dosage; first dose 09 All 32 \$16.94 No once per day	0021A *		09	All			\$16.94	No	once per dav

						1		1
0021A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose	24	240, 247	11, 31, 32, 99		\$16.94	No	once per day
0021A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose	31	All	11, 12, 31, 32		\$16.94	No	once per day
0021A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; first dose	33	335	11, 12		\$16.94	No	once per day
0022A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose	01	183	22		\$28.39	No	once per day
0022A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose	08	082	49		\$28.39	No	once per day

	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector,							
	preservative free, 5x1010 viral			11, 12, 31,				
0022A *	particles/0.5mL dosage; second dose	09	All	32		\$28.39	No	once per day
0022A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose	24	240, 247	11, 31, 32, 99		\$28.39	No	once per day
0022A *	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage; second dose	31	All	11, 12, 31, 32		\$28.39	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral	~~						
0022A *	particles/0.5mL dosage; second dose	33	335	11, 12		\$28.39	No	once per day

* These codes were added to the MA Program Fee Schedule, effective February 1, 2021.